MedTrace Logo

Dynepo Long-Term Safety Study

NCT00514813 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2021-07-13

Study results available
· View outcomes & findings →

Summary

To assess the incidence rate of Treatment Emergent Adverse Events (TEAEs) over 2 years in patients treated with Dynepo.

Conditions

  • Anemia
  • Kidney Failure, Chronic

Interventions

DRUG

Dynepo

Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-06
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514813 on ClinicalTrials.gov